Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer. (HealthDay News) — For patients with microsatellite-instability-high (MSI-H) ...
New NSCLC guideline updates outline expanded perioperative immunotherapy, adjuvant targeted therapy, and consolidation ...
Trial participants were randomly assigned to receive neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks. HealthDay News — For patients with resectable ...
Adding nivolumab (Opdivo) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-1 inhibitor alone significantly increased event-free survival (EFS) for patients with resectable ...
The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population. The trial showed the combination significantly ...
Approval based on results from the CheckMate-77T trial which showed perioperative Opdivo improved event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant ...
Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors Patients with unresectable, ...
(San Diego, Calif--September 8, 2024, 10:05 a.m. PCT) – New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who ...
Treatment with nivolumab plus cisplatin and gemcitabine reduced the risk of death by 22% and reduced the risk for disease progression or death by 28% vs chemotherapy alone. The Food and Drug ...
Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive bladder ...
Significantly more patients had 18-month event-free survival in nivolumab vs chemotherapy group. HealthDay News — For patients with resectable non-small cell lung cancer (NSCLC), perioperative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback